Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 booster-dose safety study of Pn MAPS30plus versus Prevenar 20 in toddlers
PACTR202605631649775Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of Prevnar 20 in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Solicited adverse events within 7 days after vaccination, Unsolicited adverse events within 1 month after vaccination and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on PACTR202605631649775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605631649775.